Skip to main content

Table 1 Characteristics of total patients with metastatic bone disease

From: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

Factors BP group
N = 262
Non-BP group
N = 55
P-value||
Age, median years (range) 45.5 (25–77) 50 (30–68) NS*
PS** (ECOG ≥ 2) 10/166 (6.0%) 2/27 (7.4%) NS
Pre-menopausal 79/176 (44.9%) 7/30 (23.3%) 0.027
Post-menopausal 97/176 (55.1%) 23/30 (76.7%)  
ER***/PR positive 202 (77.1%) 28 (50.9%) < 0.001
HER2 positive 72 (27.5%) 23 (41.8%) 0.035
DFI (month, median, range) 25 (0–230) 21 (0–174) NS
Initial stage IV 61 (23.4%) 11 (20%) NS
Adjuvant treatment    
   Radiotherapy 111 (42.4%) 27 (49.1%) NS
   Chemotherapy 176 (67.2%) 38 (69.1%) NS
   Hormonal therapy 127 (48.5%) 21 (38.2%) NS
Metastatic sites    
   Visceral (liver, lung) 116 (44.3%) 37 (67.3%) 0.002
   LNs§ 119 (45.4%) 30 (54.5%) NS
   Soft tissue 78 (29.8%) 20 36.4%) NS
   Bone only 81 (30.9%) 8 (14.5%) 0.014
   Weight bearing bone involvement 225 (86.2%) 25 (45.5%) < 0.001
   Sum of metastatic sites (range) 2 (1–6) 3 (1–6) 0.006
Cycles of palliative chemotherapy    NS
   1 36 (13.7%) 8 (14.5%)  
   2 53 (20.2%) 13 (23.6%)  
   ≥ 3 157 (59.9%) 29 (52.7%)  
Palliative AI use 168 (64.1%) 23 (41.8%) 0.002
Palliative anti-HER2 therapy 58/72 (80.6%) 20/23 (86.9%) NS
Disease progression in bone (n) 97 (47.8%) 21 (38.2%) NS
SREs (except the first event) 63 (27.2%) 21 (24.7%) NS
  1. Abbreviations:*, not significant; **, performance status; ***, estrogen receptor; †, progesteron receptor;
  2. ‡, disease free interval; § lymph nodes; ¶ aromatase inhibitor; ||, P-value was obtained by chi-square test except variables of age and DFI which were obtained through Mann-Whitney U test